{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:31:50Z","timestamp":1790271110196,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T00:00:00Z","timestamp":1332374400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pierre-Robin sequence (PRS) is defined by micro- and\/or retrognathia, glossoptosis and cleft soft palate, either caused by deformational defect or part of a malformation syndrome. Neurofibromatosis type 2 (NF2) is an autosomal dominant syndrome caused by mutations in the <jats:italic>NF2<\/jats:italic> gene on chromosome 22q12.2. NF2 is characterized by bilateral vestibular schwannomas, spinal cord schwannomas, meningiomas and ependymomas, and juvenile cataracts. To date, NF2 and PRS have not been described together in the same patient.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>We report a female with PRS (micrognathia, cleft palate), microcephaly, ocular hypertelorism, mental retardation and bilateral hearing loss, who at age 15 was also diagnosed with severe NF2 (bilateral cerebellopontine schwannomas and multiple extramedullary\/intradural spine tumors). This is the first published report of an individual with both diagnosed PRS and NF2. High resolution karyotype revealed 46, XX, del(22)(q12.1q12.3), FISH confirmed a deletion encompassing <jats:italic>NF2<\/jats:italic>, and chromosomal microarray identified a 3,693 kb deletion encompassing multiple genes including <jats:italic>NF2<\/jats:italic> and <jats:italic>MN1<\/jats:italic> (meningioma 1).<\/jats:p>\n            <jats:p>Five additional patients with craniofacial dysmorphism and deletion in chromosome 22-adjacent-to or containing <jats:italic>NF2<\/jats:italic> were identified in PubMed and the DECIPHER clinical chromosomal database. Their shared chromosomal deletion encompassed <jats:italic>MN1<\/jats:italic>, <jats:italic>PITPNB<\/jats:italic> and <jats:italic>TTC28<\/jats:italic>. <jats:italic>MN1<\/jats:italic>, initially cloned from a patient with meningioma, is an oncogene in murine hematopoiesis and participates as a fusion gene (<jats:italic>TEL<\/jats:italic>\/<jats:italic>MN1<\/jats:italic>) in human myeloid leukemias. Interestingly, <jats:italic>Mn1<\/jats:italic>-haploinsufficient mice have abnormal skull development and secondary cleft palate. Additionally, <jats:italic>Mn1<\/jats:italic> regulates maturation and function of calvarial osteoblasts and is an upstream regulator of <jats:italic>Tbx22<\/jats:italic>, a gene associated with murine and human cleft palate. This suggests that deletion of <jats:italic>MN1<\/jats:italic> in the six patients we describe may be causally linked to their cleft palates and\/or craniofacial abnormalities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Thus, our report describes a <jats:italic>NF2<\/jats:italic>-adjacent chromosome 22q12.2 deletion syndrome and is the first to report association of <jats:italic>MN1<\/jats:italic> deletion with abnormal craniofacial development and\/or cleft palate in humans.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2350-13-19","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T01:41:40Z","timestamp":1332466900000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature"],"prefix":"10.1186","volume":"13","author":[{"given":"Tom B","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A","family":"Sanchez-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Panigrahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Erdreich-Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,22]]},"reference":[{"key":"932_CR1","first-page":"37","volume":"89","author":"P Robin","year":"1923","unstructured":"Robin P: La chute de la base de la langue consideree comme une nouvelle cause de gene dans la respiration naso-pharyngienne. Bull Acad Med (Paris). 1923, 89: 37-","journal-title":"Bull Acad Med (Paris)"},{"issue":"6","key":"932_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.ijporl.2005.10.016","volume":"70","author":"AK Evans","year":"2006","unstructured":"Evans AK, Rahbar R, Rogers GF, Mulliken JB, Volk MS: Robin sequence: a retrospective review of 115 patients. Int J Pediatr Otorhinolaryngol. 2006, 70 (6): 973-980. 10.1016\/j.ijporl.2005.10.016.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"1","key":"932_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s004310000646","volume":"160","author":"AP van den Elzen","year":"2001","unstructured":"van den Elzen AP, Semmekrot BA, Bongers EM, Huygen PL, Marres HA: Diagnosis and treatment of the Pierre Robin sequence: results of a retrospective clinical study and review of the literature. Eur J Pediatr. 2001, 160 (1): 47-53. 10.1007\/s004310000646.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"932_CR4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1067\/mpd.2001.117784","volume":"139","author":"M Holder-Espinasse","year":"2001","unstructured":"Holder-Espinasse M, Abadie V, Cormier-Daire V, Beyler C, Manach Y, Munnich A, Lyonnet S, Couly G, Amiel J: Pierre Robin sequence: a series of 117 consecutive cases. J Pediatr. 2001, 139 (4): 588-590. 10.1067\/mpd.2001.117784.","journal-title":"J Pediatr"},{"issue":"11","key":"932_CR5","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jpedsurg.2009.04.018","volume":"44","author":"KW Butow","year":"2009","unstructured":"Butow KW, Hoogendijk CF, Zwahlen RA: Pierre Robin sequence: appearances and 25 years of experience with an innovative treatment protocol. J Pediatr Surg. 2009, 44 (11): 2112-2118. 10.1016\/j.jpedsurg.2009.04.018.","journal-title":"J Pediatr Surg"},{"issue":"2","key":"932_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1597\/05-008.1","volume":"43","author":"LP Jakobsen","year":"2006","unstructured":"Jakobsen LP, Knudsen MA, Lespinasse J, Garcia Ayuso C, Ramos C, Fryns JP, Bugge M, Tommerup N: The genetic basis of the Pierre Robin Sequence. Cleft Palate Craniofac J. 2006, 43 (2): 155-159. 10.1597\/05-008.1.","journal-title":"Cleft Palate Craniofac J"},{"issue":"1","key":"932_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1597\/02-055","volume":"41","author":"A Printzlau","year":"2004","unstructured":"Printzlau A, Andersen M: Pierre Robin sequence in Denmark: a retrospective population-based epidemiological study. Cleft Palate Craniofac J. 2004, 41 (1): 47-52. 10.1597\/02-055.","journal-title":"Cleft Palate Craniofac J"},{"issue":"4","key":"932_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/0007-1226(83)90123-6","volume":"36","author":"PG Bush","year":"1983","unstructured":"Bush PG, Williams AJ: Incidence of the Robin Anomalad (Pierre Robin syndrome). Br J Plast Surg. 1983, 36 (4): 434-437. 10.1016\/0007-1226(83)90123-6.","journal-title":"Br J Plast Surg"},{"issue":"9","key":"932_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ijporl.2011.06.009","volume":"75","author":"F Glynn","year":"2011","unstructured":"Glynn F, Fitzgerald D, Earley MJ, Rowley H: Pierre Robin sequence: an institutional experience in the multidisciplinary management of airway, feeding and serous otitis media challenges. Int J Pediatr Otorhinolaryngol. 2011, 75 (9): 1152-1155. 10.1016\/j.ijporl.2011.06.009.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"4","key":"932_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1597\/03-166.1","volume":"42","author":"J Schubert","year":"2005","unstructured":"Schubert J, Jahn H, Berginski M: Experimental aspects of the pathogenesis of Robin sequence. Cleft Palate Craniofac J. 2005, 42 (4): 372-376. 10.1597\/03-166.1.","journal-title":"Cleft Palate Craniofac J"},{"issue":"2","key":"932_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/02844318409052844","volume":"18","author":"A Rintala","year":"1984","unstructured":"Rintala A, Ranta R, Stegars T: On the pathogenesis of cleft palate in the Pierre Robin syndrome. Scand J Plast Reconstr Surg. 1984, 18 (2): 237-240. 10.3109\/02844318409052844.","journal-title":"Scand J Plast Reconstr Surg"},{"issue":"3","key":"932_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/ng.329","volume":"41","author":"S Benko","year":"2009","unstructured":"Benko S, Fantes JA, Amiel J, Kleinjan DJ, Thomas S, Ramsay J, Jamshidi N, Essafi A, Heaney S, Gordon CT, et al: Highly conserved non-coding elements on either side of SOX9 associated with Pierre Robin sequence. Nat Genet. 2009, 41 (3): 359-364. 10.1038\/ng.329.","journal-title":"Nat Genet"},{"issue":"6","key":"932_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/jmg.2006.046177","volume":"44","author":"LP Jakobsen","year":"2007","unstructured":"Jakobsen LP, Ullmann R, Christensen SB, Jensen KE, Molsted K, Henriksen KF, Hansen C, Knudsen MA, Larsen LA, Tommerup N, et al: Pierre Robin sequence may be caused by dysregulation of SOX9 and KCNJ2. J Med Genet. 2007, 44 (6): 381-386. 10.1136\/jmg.2006.046177.","journal-title":"J Med Genet"},{"issue":"12","key":"932_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/jmg.29.12.847","volume":"29","author":"DG Evans","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Strachan T, Harris R: A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet. 1992, 29 (12): 847-852. 10.1136\/jmg.29.12.847.","journal-title":"J Med Genet"},{"issue":"12","key":"932_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/jmg.29.12.841","volume":"29","author":"DG Evans","year":"1992","unstructured":"Evans DG, Huson SM, Donnai D, Neary W, Blair V, Teare D, Newton V, Strachan T, Ramsden R, Harris R: A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992, 29 (12): 841-846. 10.1136\/jmg.29.12.841.","journal-title":"J Med Genet"},{"key":"932_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-4-16","volume":"4","author":"DG Evans","year":"2009","unstructured":"Evans DG: Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009, 4: 16-10.1186\/1750-1172-4-16.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"932_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F: Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010, 152A (2): 327-332. 10.1002\/ajmg.a.33139.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"932_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","volume":"26","author":"DG Evans","year":"2005","unstructured":"Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R: Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005, 26 (1): 93-97. 10.1097\/00129492-200501000-00016.","journal-title":"Otol Neurotol"},{"issue":"2","key":"932_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/(SICI)1098-2264(199906)25:2<184::AID-GCC15>3.0.CO;2-B","volume":"25","author":"CE Bruder","year":"1999","unstructured":"Bruder CE, Ichimura K, Blennow E, Ikeuchi T, Yamaguchi T, Yuasa Y, Collins VP, Dumanski JP: Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible localization of a neurofibromatosis type 2 modifier gene?. Genes Chromosomes Cancer. 1999, 25 (2): 184-190. 10.1002\/(SICI)1098-2264(199906)25:2<184::AID-GCC15>3.0.CO;2-B.","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"932_CR20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jmg.37.12.897","volume":"37","author":"DG Evans","year":"2000","unstructured":"Evans DG, Sainio M, Baser ME: Neurofibromatosis type 2. J Med Genet. 2000, 37 (12): 897-904. 10.1136\/jmg.37.12.897.","journal-title":"J Med Genet"},{"issue":"3","key":"932_CR21","first-page":"529","volume":"59","author":"DM Parry","year":"1996","unstructured":"Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF: Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996, 59 (3): 529-539.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"932_CR22","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/jmg.35.6.450","volume":"35","author":"DG Evans","year":"1998","unstructured":"Evans DG, Trueman L, Wallace A, Collins S, Strachan T: Genotype\/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet. 1998, 35 (6): 450-455. 10.1136\/jmg.35.6.450.","journal-title":"J Med Genet"},{"issue":"2","key":"932_CR23","first-page":"331","volume":"59","author":"MH Ruttledge","year":"1996","unstructured":"Ruttledge MH, Andermann AA, Phelan CM, Claudio JO, Han FY, Chretien N, Rangaratnam S, MacCollin M, Short P, Parry D, et al: Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996, 59 (2): 331-342.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"932_CR24","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1212\/01.WNL.0000035638.74084.F4","volume":"59","author":"ME Baser","year":"2002","unstructured":"Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG: Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology. 2002, 59 (11): 1759-1765.","journal-title":"Neurology"},{"issue":"2","key":"932_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1086\/422700","volume":"75","author":"ME Baser","year":"2004","unstructured":"Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Gillespie JE, Ramsden RT, Evans DG: Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet. 2004, 75 (2): 231-239. 10.1086\/422700.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"932_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1212\/01.wnl.0000201190.89751.41","volume":"66","author":"ME Baser","year":"2006","unstructured":"Baser ME, Friedman JM, Evans DG: Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology. 2006, 66 (5): 730-732. 10.1212\/01.wnl.0000201190.89751.41.","journal-title":"Neurology"},{"issue":"3","key":"932_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/hmg\/10.3.271","volume":"10","author":"CE Bruder","year":"2001","unstructured":"Bruder CE, Hirvela C, Tapia-Paez I, Fransson I, Segraves R, Hamilton G, Zhang XX, Evans DG, Wallace AJ, Baser ME, et al: High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet. 2001, 10 (3): 271-282. 10.1093\/hmg\/10.3.271.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"932_CR28","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1136\/jmg.39.2.e6","volume":"39","author":"G Barbi","year":"2002","unstructured":"Barbi G, Rossier E, Vossbeck S, Hummler H, Lang D, Flock F, Terinde R, Wirth J, Vogel W, Kehrer-Sawatzki H: Constitutional de novo interstitial deletion of 8 Mb on chromosome 22q12.1-12.3 encompassing the neurofibromatosis type 2 (NF2) locus in a dysmorphic girl with severe malformations. J Med Genet. 2002, 39 (2): E6-10.1136\/jmg.39.2.e6.","journal-title":"J Med Genet"},{"issue":"6","key":"932_CR29","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/ajmg.a.33961","volume":"155A","author":"E Said","year":"2011","unstructured":"Said E, Cuschieri A, Vermeesch J, Fryns JP: Toriello-Carey syndrome with a 6 Mb interstitial deletion at 22q12 detected by array CGH. Am J Med Genet A. 2011, 155A (6): 1390-1392.","journal-title":"Am J Med Genet A"},{"key":"932_CR30","unstructured":"DECIPHER. accessed March 1; 2011, [http:\/\/decipher.sanger.ac.uk\/]"},{"issue":"2","key":"932_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1399-0004.2009.01315.x","volume":"77","author":"SK Selvanathan","year":"2010","unstructured":"Selvanathan SK, Shenton A, Ferner R, Wallace AJ, Huson SM, Ramsden RT, Evans DG: Further genotype-phenotype correlations in neurofibromatosis 2. Clin Genet. 2010, 77 (2): 163-170. 10.1111\/j.1399-0004.2009.01315.x.","journal-title":"Clin Genet"},{"issue":"6","key":"932_CR32","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1093\/hmg\/2.6.701","volume":"2","author":"CJ Watson","year":"1993","unstructured":"Watson CJ, Gaunt L, Evans G, Patel K, Harris R, Strachan T: A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Hum Mol Genet. 1993, 2 (6): 701-704. 10.1093\/hmg\/2.6.701.","journal-title":"Hum Mol Genet"},{"issue":"13","key":"932_CR33","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1093\/hmg\/7.13.2095","volume":"7","author":"J Zucman-Rossi","year":"1998","unstructured":"Zucman-Rossi J, Legoix P, Der Sarkissian H, Cheret G, Sor F, Bernardi A, Cazes L, Giraud S, Ollagnon E, Lenoir G, et al: NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet. 1998, 7 (13): 2095-2101. 10.1093\/hmg\/7.13.2095.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"932_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/jmg.37.1.75","volume":"37","author":"C Lopez-Correa","year":"2000","unstructured":"Lopez-Correa C, Zucman-Rossi J, Brems H, Thomas G, Legius E: NF2 gene deletion in a family with a mild phenotype. J Med Genet. 2000, 37 (1): 75-77. 10.1136\/jmg.37.1.75.","journal-title":"J Med Genet"},{"issue":"8","key":"932_CR35","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/hmg\/2.8.1215","volume":"2","author":"M Sanson","year":"1993","unstructured":"Sanson M, Marineau C, Desmaze C, Lutchman M, Ruttledge M, Baron C, Narod S, Delattre O, Lenoir G, Thomas G, et al: Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus. Hum Mol Genet. 1993, 2 (8): 1215-1220. 10.1093\/hmg\/2.8.1215.","journal-title":"Hum Mol Genet"},{"issue":"24","key":"932_CR36","doi-asserted-by":"publisher","first-page":"9281","DOI":"10.1128\/MCB.20.24.9281-9293.2000","volume":"20","author":"A Buijs","year":"2000","unstructured":"Buijs A, van Rompaey L, Molijn AC, Davis JN, Vertegaal AC, Potter MD, Adams C, van Baal S, Zwarthoff EC, Roussel MF, et al: The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. Mol Cell Biol. 2000, 20 (24): 9281-9293. 10.1128\/MCB.20.24.9281-9293.2000.","journal-title":"Mol Cell Biol"},{"issue":"8","key":"932_CR37","first-page":"1521","volume":"10","author":"RH Lekanne Deprez","year":"1995","unstructured":"Lekanne Deprez RH, Riegman PH, Groen NA, Warringa UL, van Biezen NA, Molijn AC, Bootsma D, de Jong PJ, Menon AG, Kley NA, et al: Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene. 1995, 10 (8): 1521-1528.","journal-title":"Oncogene"},{"issue":"10","key":"932_CR38","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1128\/MCB.25.10.4229-4236.2005","volume":"25","author":"MA Meester-Smoor","year":"2005","unstructured":"Meester-Smoor MA, Vermeij M, van Helmond MJ, Molijn AC, van Wely KH, Hekman AC, Vermey-Keers C, Riegman PH, Zwarthoff EC: Targeted disruption of the Mn1 oncogene results in severe defects in development of membranous bones of the cranial skeleton. Mol Cell Biol. 2005, 25 (10): 4229-4236. 10.1128\/MCB.25.10.4229-4236.2005.","journal-title":"Mol Cell Biol"},{"issue":"23","key":"932_CR39","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1242\/dev.025304","volume":"135","author":"W Liu","year":"2008","unstructured":"Liu W, Lan Y, Pauws E, Meester-Smoor MA, Stanier P, Zwarthoff EC, Jiang R: The Mn1 transcription factor acts upstream of Tbx22 and preferentially regulates posterior palate growth in mice. Development. 2008, 135 (23): 3959-3968. 10.1242\/dev.025304.","journal-title":"Development"},{"issue":"27","key":"932_CR40","doi-asserted-by":"publisher","first-page":"18174","DOI":"10.1074\/jbc.M109.001354","volume":"284","author":"X Zhang","year":"2009","unstructured":"Zhang X, Dowd DR, Moore MC, Kranenburg TA, Meester-Smoor MA, Zwarthoff EC, MacDonald PN: Meningioma 1 is required for appropriate osteoblast proliferation, motility, differentiation, and function. J Biol Chem. 2009, 284 (27): 18174-18183. 10.1074\/jbc.M109.001354.","journal-title":"J Biol Chem"},{"issue":"21","key":"932_CR41","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1093\/hmg\/ddp368","volume":"18","author":"E Pauws","year":"2009","unstructured":"Pauws E, Hoshino A, Bentley L, Prajapati S, Keller C, Hammond P, Martinez-Barbera JP, Moore GE, Stanier P: Tbx22null mice have a submucous cleft palate due to reduced palatal bone formation and also display ankyloglossia and choanal atresia phenotypes. Hum Mol Genet. 2009, 18 (21): 4171-4179. 10.1093\/hmg\/ddp368.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"932_CR42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/jmg.2003.010868","volume":"41","author":"AC Marcano","year":"2004","unstructured":"Marcano AC, Doudney K, Braybrook C, Squires R, Patton MA, Lees MM, Richieri-Costa A, Lidral AC, Murray JC, Moore GE, et al: TBX22 mutations are a frequent cause of cleft palate. J Med Genet. 2004, 41 (1): 68-74. 10.1136\/jmg.2003.010868.","journal-title":"J Med Genet"},{"issue":"2","key":"932_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/ng730","volume":"29","author":"C Braybrook","year":"2001","unstructured":"Braybrook C, Doudney K, Marcano AC, Arnason A, Bjornsson A, Patton MA, Goodfellow PJ, Moore GE, Stanier P: The T-box transcription factor gene TBX22 is mutated in X-linked cleft palate and ankyloglossia. Nat Genet. 2001, 29 (2): 179-183. 10.1038\/ng730.","journal-title":"Nat Genet"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-13-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2350-13-19\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-13-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2350-13-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:54:41Z","timestamp":1630522481000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/1471-2350-13-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,22]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1186\/1471-2350-13-19","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,22]]},"assertion":[{"value":"6 September 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"19"}}